Drug Profile
BIRT 2584 XX
Alternative Names: BIRT 2584; BIRT2584XX; integrin inhibitors - Boehringer IngelheimLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Class Anti-inflammatories; Antipsoriatics
- Mechanism of Action Integrin alpha chain inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Multiple sclerosis; Psoriasis
Most Recent Events
- 03 May 2007 Discontinued - Phase-II for Psoriasis in Canada (PO)
- 03 May 2007 Discontinued - Phase-II for Psoriasis in European Union (PO)
- 15 Jan 2007 Discontinued - Phase-II for Multiple sclerosis in European Union (PO)